HIV screening strategies in blood donors: a cost-effectiveness analysis
10.13303/j.cjbt.issn.1004-549x.2024.01.007
- VernacularTitle:献血者HIV检测策略的成本效果分析
- Author:
Hui HUANG
1
;
Tao ZHOU
2
;
Zheng ZHU
3
;
Yi MA
1
;
Li CHEN
1
;
Wanping DUAN
1
;
Ling LI
4
Author Information
1. Wuhu Blood Center, Wuhu 241002, China
2. Huainan Blood Center
3. Xuancheng Blood Center
4. The Third People’s Hospital of Chengdu
- Publication Type:Journal Article
- Keywords:
HIV screening;
decision tree model;
cost-effectiveness analysis
- From:
Chinese Journal of Blood Transfusion
2024;37(1):37-42
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To analyze the cost and effectiveness of different HIV screening strategies based on multi-center HIV residual risk study, so as to provide reference for blood centers to adopt appropriate HIV testing strategies. 【Methods】 According to the HIV screening and confirmation of blood donors in three blood centers in Anhui Province, the residual risk of different HIV screening strategies was estimated. A decision tree model was established to analyze the cost-effectiveness differences of three different screening strategies under current domestic policies. 【Results】 The residual risk of anti-HIV-1 +2 ELISA, HIV Ag/Ab1+2 ELISA and ELISA+NAT were 1.17×10-6,0.84×10-6 and 0.59×10-6, respectively. According to decision tree model analysis, HIV Ag/Ab1+2 ELISA had a cost-effectiveness advantage over anti-HIV 1+2 ELISA when there was no NAT, but the advantage of HIV Ag/Ab1+2 ELISA disappeared when there was one NAT. The cost of HIV reagents, the cost of HIV treatment and the cost of false positive discarding were sensitive factors of the model. 【Conclusion】 In this area, one anti-HIV 1+2 ELISA combined with one NAT has a cost-effectiveness advantage. Blood centers need to confirm and evaluate the ELISA reagents used before conducting HIV screening. Under the premise of ensuring sensitivity, reagent cost and reagent false positive rate are the key factors.
